Ideaya Biosciences
IDEAYA Biosciences Inc is an American precision medicine oncology company committed to the discovery and development of targeted therapeutics for cancer treatment. The company utilizes a molecular diagnostics platform to identify patient biomarkers and develop synthetic lethality therapies targeting specific genetic mutations in tumors. Its clinical-stage pipeline includes targeted oncology candidates addressing DNA damage repair, MAT2A inhibition, and other precision oncology mechanisms. Core operations encompass preclinical drug discovery, medicinal chemistry, biomarker research, and clinical trial management. As a clinical-stage biopharmaceutical firm, the company generates minimal commercial revenue and finances its operations through public equity offerings and major pharmaceutical partnerships. IDEAYA holds an emerging position in precision oncology innovation. The company is headquartered in South San Francisco, California, United States, and its common stock trades on the Nasdaq Global Select Market.
9 of the funds FundTelligence covers report a position in Ideaya Biosciences.
- Legal name
- Ideaya Biosciences Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 9
- Exposure themes
- Precision Medicine & Genomics, Precision Oncology, Precision Therapeutics
Funds holding Ideaya Biosciences
- BNP Health Care Innovators — BNP Paribas · 0.97 % (full portfolio disclosed, June 2026)
- BNP US Small Cap — BNP Paribas · 0.79 % (full portfolio disclosed, June 2026)
- Schroder ISF Healthcare Innovation — Schroders · 0.49 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.27 % (full portfolio disclosed, October 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.26 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.19 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.04 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 9 funds holding it.